Q3 2024 Stevanato Group SpA Earnings Call Transcript
Key Points
- Stevanato Group SpA (STVN) reported a 2% revenue growth in the third quarter of 2024, driven by a 6% increase in the biopharmaceutical and diagnostic solutions segment.
- High value solutions revenue grew by 17%, with high value syringes contributing significantly to this growth.
- The company achieved a major milestone with the successful launch of commercial production at its Fishers facility, generating its first commercial revenue.
- The Latina project became profitable at the gross profit level in the third quarter, indicating progress in scaling production and improving utilization.
- Stevanato Group SpA (STVN) remains confident in the long-term demand landscape for its engineering segment, supported by trends such as the rise in biologics and the adoption of drug delivery devices.
- The company lowered its full-year 2024 guidance for adjusted EBITDA and adjusted diluted EPS due to higher costs in the engineering segment and increased validation activities in the US.
- Gross profit margin decreased to 26.8% in the third quarter of 2024, impacted by vial de-stocking and underutilization of vial lines.
- The engineering segment experienced a 15% revenue decline, with higher costs related to complex projects and expenses tied to the business optimization plan.
- Net cash from operating activities was EUR18.3 million, resulting in a negative free cash flow of EUR28.4 million in the third quarter.
- The company faces uncertainty regarding the timing and pace of recovery in vial demand, which remains below 2019 levels.
Good afternoon. This is the Chorus Call conference operator. Welcome and thank you for joining the Stevanato Group third quarter 2024 earnings call. (Operator Instructions)
At this time, I would like to turn the conference over to Ms. Lisa Miles, Senior Vice President and Investor Relations. Please go ahead madam.
Good morning, and thank you for joining us. With me today is Franco Stevanato, Chairman and Chief Executive Officer; and Marco Dal Lago, Chief Financial Officer.
You can find a presentation to accompany today's results on the investor relations page of our website which can be found under the financial results tab. As a reminder, some statements being made today will be forward-looking in nature and are only predictions.
Actual events and results may differ materially as a result of the risks we face including those discussed in item 3D entitled Risk Factors in the company's most recent annual report on Form 20-F filed with the SEC on March 7, 2024
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
